FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 713 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Air Pollution and Breast Cancer Risk – A Link That Calls... October 17, 2023 Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention... April 29, 2025 What Caregivers Should Know About End-of-Life Care Issues for People With... September 8, 2022 India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration February 7, 2024 Load more HOT NEWS Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk... Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported... Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with...
